The division bench upheld the single-judge bench’s findings, which cited public interest in ensuring affordable access to SMA treatment, allowing Natco Pharma to launch a lower-cost generic despite Roche’s patent claims.
​The division bench upheld the single-judge bench’s findings, which cited public interest in ensuring affordable access to SMA treatment, allowing Natco Pharma to launch a lower-cost generic despite Roche’s patent claims. by Soban News (international And National News)
